Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Bioavailability of Fexofenadine Topical Lotion in Healthy Men
NCT05461456Phase 1Completed
- Sponsor
- OrchestratePharma
- Start
- Apr 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Fexofenadine Hydrochloride Topical Lotion 1% in atopic dermatitis (AD), sponsored by OrchestratePharma. Primary endpoints: Adverse Events, Maximum Plasma Concentration (Cmax) and 3 more. Started Apr 2022; status: completed.
02
Drugs
Fexofenadine Hydrochloride Topical Lotion 1%
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05461456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05461456.